-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new study evaluating the effectiveness of the BNT162b2 (Pfizer Biotech) vaccine against the Omicron variant shows that three doses of the vaccine can provide a sufficient level of protection against disease caused by the Omicron variant
.
The globally prevalent SARS-CoV-2 Concern Variant (VOC) Omicron (B.
"Further clinical trials and real-world data will appear soon to address the efficacy of a third dose of Omicron-mediated BNT162b2 against COVID-19," they concluded
Magazine
Science
DOI
10.
Article Title
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera